NCT05094687|CompletedDMC
Loading search results
Sponsor study identifier
observational
1,206
1 country
1
Study Start
July 31, 2020
Actual (reported)Primary Completion
August 1, 2021
Actual (reported)Study Completion
August 1, 2021
Actual (reported)An outbreak of Corona virus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-coV-2) occurred in Wuhan city, Hubei province, China in December 2019. Pulmonary health has been the main focus of studies of COVID-19, current articles show that cutaneous signs appear in COVID-19 patients, their identification may be vital to early diagnosis and lead to possible better prognosis in COVID-19 patients
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
August 1, 2021
Actual (reported)Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
July 31, 2020
Actual (reported)August 1, 2021
Actual (reported)August 1, 2021
Actual (reported)October 23, 2021
Actual (reported)October 26, 2021
Actual (reported)Frequency of skin manifestations in 1206
Frequency of skin manifestations in COVID-19 positive 1206 subjects.
From day of randomisation until development of skin manifestations or not, assessed upto 12 months
COVID-19 Disease Outcome in patients with skin manifestations
Disease outcome of COVID-19 in participants who will be having cutanous manifestations and will be classified as mild moderate and severe.
Disease outcome during this 12 months duration of study.
Cutaneous patterns
If present, type of skin manifestations to be noted
From day of randomisation until development of skin manifestations or not, assessed upto 12 months
1206 patients diagnosed case of COVID-19 by PCR.
Jinnah Postgraduate Medical Centre
Karachi, Sindh, 75510, Pakistan
Rabia Ghafoor, MBBS, FCPS, SCE-Derm(MRCP-UK)
Jinnah Postgraduate Medical Centre
Syeda Mahanum Ali, MBBS, Postgraduate Trainee
Jinnah Postgraduate Medical Centre
1,206 participants (actual enrollment reported by the registry).
First Submitted
October 23, 2021
First Posted
October 26, 2021
Study Start
July 31, 2020
Actual (reported)"Clinical Characteristics, Comorbidities and Outcome of Critically Sick Patients With COVID-19
Association of COVID-19 disease outcome in correlation with skin manifestation
It is to check if presence of skin manifestations can affect COVID-19 disease outcome
From day of randomisation until development of skin manifestations or not, until COVID-19 disease outcome (improved, worsen or death) assessed upto 12 months
Skin symptoms
If applicable, Skin symptoms as pruritis, burning or pain
From day of randomisation until development of skin manifestations or not, assessed upto 12 months
Duration of skin manifestations
For how long the skin manifestations last before resolution or whether it persisted.
From day of randomisation until development of skin manifestation or not, if development/already developed skin manifestations then resolution of it or for how long it persisted, assessed upto 12 months
The time of onset of skin manifestations
To check if skin manifestations can be an early sign of disease or a sole manifestation of COVID-19. (without, before, after or with systemic symptoms)
From day of randomisation until development of systemic manifestations or not, in patients with skin manifestations assessed upto 12 months
Presence or absence of systemic symptoms in COVID-19 patients
To check if skin manifestations can be a sole presentation of COVID-19
Day 1 of randomisation until development of systemic symptoms in patients with skin manifestations in upto 12 months
Latency between the cutaneous manifestations and development of systemic symptoms of COVID-19
From day of randomisation until development of skin/systemic manifestations or not, assessed upto 12 months
Duration of systemic symptoms
From day of randomisation to recovery or death, and also duration of symptoms prior to coming for consultation/hospital, assessed upto 12 months
Type of systemic symptoms
From day of randomisation until development of systemic symptoms or not, assessed upto 12 months
age of patients
Day 1 of randomisation until development of skin manifestations in upto 12 months
comorbidities
Day 1 of randomisation until development of skin manifestations in upto 12 months
Contact the study team to confirm eligibility.
Primary Completion
August 1, 2021
Actual (reported)Study Completion
August 1, 2021
Actual (reported)Last Updated
November 22, 2021
Record last verified: 2021-11
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: